武汉招聘

上海睿星基因是一家定位于全球布局的生物医药高新技术企业。2001年公司由留美科学家罗楹博士等归国创立，2005年与日本GNI公司合并。多年来在多个疾病领域建立了丰富的新药开发管线，如肝硬化、肺纤维化、骨科修复、癌症等。公司已获得1个1.1类新药证书，另有3个1.1类新药同时在美国和中国开发，是国内少有的能独立进行整体新药开发并获批一类新药的公司。

Cullgen Inc.是集团2018年成立的子公司，总部位于美国圣地亚哥，研发中心位于上海浦东。Cullgen致力于为缺乏有效药物的关键致病蛋白开发全新靶向药物，其技术核心为泛素介导的靶向蛋白降解技术PROTAC/uSMITE（ubiquitin-mediated, small molecule-induced target elimination technology）。该技术已成为小分子药物开发的最热领域，被广泛认为将引领新药开发的下一次革命。Cullgen在全球这一领域中处于领先地位。

我们的研发团队正处在高速发展阶段，真诚欢迎富有创新精神、专业技能和管理能力的时代精英加入我们。公司提供富有竞争力的薪酬，广阔的个人发展空间，鼓励共同合作、学习的工作环境。让我们在国际化的企业文化氛围中共同成长！

Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, uSMITE, based on recent advances in the science of protein degradation. Typically, drugs are designed to interact with the functional sites of proteins and block their activities. We are developing uSMITE to expand the drug design paradigm beyond functional site inhibition, to make it possible to eliminate previously “undruggable” enzymes and proteins by targeted destruction. We also intend to use the uSMITE technology to harness the ubiquitin proteasome system, a multi-step biochemical process that controls protein degradation in all cells. From years of research on the proteasome system and key discoveries about its assembly, Cullgen’s founders have already demonstrated that the underlying technology can rapidly generate a large number of highly potent, selective, and bioavailable compounds. Furthermore, this process is significantly more cost effective compared with traditional drug discovery approaches.

公司官网：*******************************； **********************；